Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-arm, phase 4 trial

Autor: Frederikus A Klok, Gerrit Toenges, Anna C Mavromanoli, Stefano Barco, Walter Ageno, Hélène Bouvaist, Marianne Brodmann, Claudio Cuccia, Francis Couturaud, Claudia Dellas, Konstantinos Dimopoulos, Daniel Duerschmied, Klaus Empen, Pompilio Faggiano, Emile Ferrari, Nazzareno Galiè, Marcello Galvani, Alexandre Ghuysen, George Giannakoulas, Menno V Huisman, David Jiménez, Matija Kozak, Irene Marthe Lang, Mareike Lankeit, Nicolas Meneveau, Thomas Münzel, Massimiliano Palazzini, Antoniu Octavian Petris, Giancarlo Piovaccari, Aldo Salvi, Sebastian Schellong, Kai-Helge Schmidt, Franck Verschuren, Irene Schmidtmann, Guy Meyer, Stavros V Konstantinides, Jaime Antonio, Abelaira Freire, Ibrahim Akin, Toni Anusic, Dorothea Becker, Laurent Bertoletti, Giuseppe Bettoni, Harald Binder, Regina Carels, Giuseppe Di Pasquale, Daniel Dürschmied, Iolanda Enea, Joachim Ficker, Sabine Genth-Zotz, Philippe Girard, Stanislav Gorbulev, Matthias Held, Lukas Hobohm, Menno V. Huisman, Frederikus A. Klok, Stavros V. Konstantinides, Kai Kronfeld, Walter Lehmacher, Concepcion Patricia Lopez Miguel, Nadine Martin, Anna Mavromanoli, Roman Pareznik, Kurt Quitzau, Irinel Raluca Parepa, Purificacion Ramirez Martin, Marc Righini, Silviu Bogdan Todea, Adam Torbicki, Luca Valerio, Thomas Vanassche, Luminita Animarie Vida-Simiti, Anamaria Wolf-Pütz

Publikováno v: Lancet Haematology, 8(9), E627-E636. ELSEVIER SCI LTD

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duratio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ea94fc56b7389498bc4106f1c7b4d3
http://hdl.handle.net/1887/3230159

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

Autor: Joachim H. Ficker, Franck Verschuren, Irene M. Lang, Thomas Münzel, Guy Meyer, Matthias Held, Frederikus A. Klok, Antoniu Petris, Menno V. Huisman, Pompilio Faggiano, Stavros Konstantinides, David Jiménez, Matija Kozak, Anamaria Wolf-Puetz, Piotr Pruszczyk, Alexandre Ghuysen, Daniel Duerschmied, Kai-Helge Schmidt, Harald Binder, Mareike Lankeit, Peitho Investigators, Nazzareno Galiè, Sebastian Schellong, Kurt Quitzau, Stefano Barco, Klaus Empen, Branislav Stefanovic, Benjamin Brenner, Walter Ageno, Nadine Heydenreich

Publikováno v: Thrombosis and Haemostasis, 117(12), 2425-2434

Patients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d33a043aaa68f8d4468db8699a30507
https://hdl.handle.net/1887/95162

[Follow-up after acute pulmonary embolism. A prospective non-interventional multi-center cohort study (FOCUS)]

Autor: Stavros V, Konstantinides, Mareike, Lankeit, Philipp, Wild, Kurt, Quitzau, Harald, Binder

Publikováno v: Deutsche medizinische Wochenschrift (1946). 140

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4c352b97ffa68bd7ccce8602e2a51505
https://pubmed.ncbi.nlm.nih.gov/26069042

Erratum to Barco et al. 'Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial' (Thromb Haemost 2016; 116: 191-197)

Autor: Klaus Empen, David Jiménez, Sebastian Schellong, Kurt Quitzau, Michael Christ, Daniel Duerschmied, Christine Espinola-Klein, Martin Schwaiblmair, Matthias Held, Stavros Konstantinides, Jan Beyer-Westendorf, Rupert Bauersachs, Cândida Fonseca, Harald Binder, Mareike Lankeit, Philipp S. Wild, Cecilia Becattini, Stefano Barco

Publikováno v: Thrombosis and Haemostasis. 116:775

[This corrects the article DOI: 10.1160/TH16-01-0004.].

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ee5746a8213185aa46458c037d9408
https://doi.org/10.1160/th16100001

CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease--the ENCORE Trials

Autor: Ingrid Fleming, Thomas F. Lüscher, Kurt Quitzau, Matthias Hermann, Thomas Münzel, Michael M. Hoffmann, J.P. Hellermann, Thomas Meinertz, Theo Gasser

Publikováno v: Atherosclerosis. 207(2)

Background Cytochrome P450 (CYP) is expressed in the human endothelium and metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic and 20-hydroxyeicosatetraenoic acids. CYP enzymes have been linked to hypertension and generation of reactive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aec01b0d5d15f998502282b5b8920e1
https://pubmed.ncbi.nlm.nih.gov/19615687